secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2021-11-15T23:59:59+00:00
Accession:  0001564590-21-057008
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Q3 net loss $11.4M; CAHmelia-203 topline delayed to 2023; CEO retired
----------------------------------------------------------------------------

- Net loss of $11.4M for Q3 2021; cash and investments $131.3M as of Sep 30.
- R&D expenses $8.6M (Q3 2021) vs $7.8M (Q3 2020); G&A $2.8M vs $1.8M.
- CAHmelia-203 topline results now expected in 2023 due to COVID-19 enrollment impact.
- Phase 2 trials in pediatric CAH and PCOS remain on track for initiation.
- CEO Richard King retired; Executive Chairman Mike Grey appointed Interim CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000156459021057008/0001564590-21-057008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000156459021057008/sprb-8k_20211115.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-057008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer